Furuya Kei, Nakajima Masao, Tokumitsu Yukio, Shindo Yoshitaro, Matsui Hiroto, Kimura Yuta, Nakagami Yuki, Watanabe Yusaku, Tomochika Shinobu, Maeda Noriko, Iida Michihisa, Takahashi Hidenori, Ioka Tatsuya, Ueno Tomio, Nagano Hiroaki
Department of Gastroenterological, Breast, and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami Kogushi, Ube, Yamaguchi, 755 8505, Japan.
Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Okayama, 701-0192, Japan.
BMC Surg. 2025 Oct 3;25(1):434. doi: 10.1186/s12893-025-03169-0.
Effective postoperative pain management is crucial after minimally invasive hepatectomy (MIH) to promote recovery, and multimodal analgesia strategies are used to reduce opioid requirements and improve outcomes. Acetaminophen is commonly included as part of multimodal therapies for postoperative pain management. However, the safety and efficacy of acetaminophen for postoperative analgesia in MIH remains unestablished due to its hepatic metabolism. This study aimed to evaluate the safety and efficacy of routine intravenous acetaminophen administration following MIH.
The data of consecutive 50 patients who had undergone MIH were retrospectively analyzed. Regarding postoperative analgesia, patients were allocated to either the opioid-alone cohort (Cohort O) or opioid with routine intravenous acetaminophen cohort (Cohort A). Analgesic efficacy was evaluated using the numerical rating scale (NRS) over the first 2 postoperative days. The sum of opioid rescue doses and frequency of postoperative nausea and vomiting (PONV) were assessed. Analgesic safety was determined by monitoring prolonged elevated transaminase levels.
Postoperatively, no significant differences in the hepatic and renal functions and systemic inflammatory markers were observed between the two cohorts. On both postoperative day 1 and day 2, Cohort A showed significantly lower NRS scores than Cohort O. Notably, almost all patients in Cohort A did not require any rescue opioid doses, resulting in a significantly reduced median rescue dose (6 versus 0 doses, p = 0.0017). Even when opioid doses were reduced due to PONV, Cohort A continued to exhibit significantly lower NRS scores.
Multimodal analgesia comprising routine intravenous acetaminophen administration could be safe and effective after minimally invasive hepatectomy, without adverse effects regarding hepatic function.
微创肝切除术后有效的疼痛管理对于促进恢复至关重要,多模式镇痛策略用于减少阿片类药物的需求并改善预后。对乙酰氨基酚通常作为术后疼痛管理多模式治疗的一部分。然而,由于其肝脏代谢,对乙酰氨基酚用于微创肝切除术后镇痛的安全性和有效性尚未确立。本研究旨在评估微创肝切除术后常规静脉注射对乙酰氨基酚的安全性和有效性。
回顾性分析连续50例行微创肝切除术患者的数据。关于术后镇痛,患者被分为单纯阿片类药物组(O组)或阿片类药物联合常规静脉注射对乙酰氨基酚组(A组)。在术后前两天使用数字评分量表(NRS)评估镇痛效果。评估阿片类药物解救剂量总和及术后恶心呕吐(PONV)的发生率。通过监测转氨酶水平持续升高来确定镇痛安全性。
术后,两组之间在肝肾功能和全身炎症指标方面未观察到显著差异。在术后第1天和第2天,A组的NRS评分均显著低于O组。值得注意的是,A组几乎所有患者都不需要任何阿片类药物解救剂量,导致中位解救剂量显著降低(6剂对0剂,p = 0.0017)。即使因PONV减少阿片类药物剂量,A组的NRS评分仍显著较低。
微创肝切除术后,包含常规静脉注射对乙酰氨基酚的多模式镇痛可能是安全有效的,且对肝功能无不良影响。